Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
0 competitors in Chronic Rhinosinusitis With Nasal Polyps
View Full LandscapeTarget Indication
Chronic Rhinosinusitis With Nasal Polyps
Clinical Trial
NCT04851964Last updated: 1/2/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Tezspire
AsthmaTezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. Chronic rhinosinusitis with nasal polyps (CRSwNP) Tezspire is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids, and/or surgery do not provide adequate disease control.
View on EMA